Thus, application of ALA and EDA as allosteric agonists of GPR120 activates a cAMP-independent non-canonical Gαi1 signaling pathway, hence generating the therapeutic effects against amyloid pathology in mouse preclinical models of AD. Here, FFAR4 is linked to amyloidosis.